Content
@
https://opensea.io/collection/science-14
0 reply
0 recast
0 reaction
arob.base.eth
@arob1000
Very excited to announce that we’ve dosed our first patient with our latest next-gen cancer immunotherapy drug which is broadly applicable to most solid tumors! We started working on this one in 2022. It’s really cool to see how quickly a drug can go from an idea into the clinic. https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-EGFR-Targeting-PRO-XTEN-Dual-Masked-T-Cell-Engager-VIR-5525-for-the-Treatment-of-Solid-Tumors/default.aspx
11 replies
8 recasts
29 reactions
Melissa Burr 🍓
@burrrrrberry
Incredible Thanks for sharing 420 $tipn
1 reply
0 recast
2 reactions
ArtStudio48
@artstudio48
OMG, I saw the NASDAQ nod on LinkedIn today, congrats 🎉
1 reply
0 recast
1 reaction
BOⓂ️B 🎩
@drmat
100 👏 Grats, Mr. Richard Lepke 😉
1 reply
0 recast
1 reaction
Saint
@saintiipapi
Congrats on the milestone
1 reply
0 recast
1 reaction
cyrus
@cyrus
Congrats this sounds very promising !
1 reply
0 recast
1 reaction
kelborhal78
@kelborhal78
Probably can't keep us updated due laws and stuff like NDAs 😅. Really interested in this trial 🫡
1 reply
0 recast
1 reaction
Pommommam
@pommommam
This kind of progress in next-gen cancer immunotherapy offers immense hope for so many. Congratulations to the entire team on this remarkable achievement! 300 $tipn
1 reply
0 recast
0 reaction
Manu Williams 🎩🔵🏒
@manuwilliams
That’s great progress Arob! I hope it is successful! 431 $degen
0 reply
0 recast
0 reaction
Lili🎩🟧
@lilim
This is the hope of humanity.
0 reply
0 recast
0 reaction
